Mayo Clinic announces the launch of CANCP, a new gene panel cancer test to help tailor chemotherapy to the individual patient based on the unique genomic signature of the patient's tumor. CANCP, an abbreviation for Solid Tumor Targeted Cancer Gene Panel by Next-Generation Sequencing, scans specific regions in 50 genes known to affect tumor growth and response to chemotherapy. The test is now available to Mayo Clinic patients and to providers worldwide through Mayo Medical Laboratories.
"Every patient's cancer is different, and oncology is moving away from treating cancer based on its location in the body in favor of selecting the best medication for the individual patient based on molecular changes in the tumor," says Axel Grothey, M.D., a Mayo Clinic oncologist who orders CANCP on selected tumors. "This test helps providers identify such molecular changes without infusing irrelevant details from genes that we know will not affect our choice of medications."
The test is a hotspot panel, which means it scans specific regions of individual genes—rather than the entire gene—in search of tumor mutations that influence response to chemotherapy. It is designed for testing of solid tumors and focuses on clinically actionable alterations.
"We worked closely with oncologists, pathologists and molecular geneticists to develop and implement a next-generation sequencing assay that will have actionable results for providers," says Benjamin Kipp, Ph.D., a Mayo Clinic molecular geneticist and CANCP's lead designer. "This test focuses on results that oncologists can use to help find the right drug the first time."
Testing is conducted in the CLIA-certified Next-Generation Sequencing Lab of the Mayo Clinic Department of Laboratory Medicine and Pathology (DLMP). This is the second next-generation sequencing panel test offered by DLMP and Mayo Medical Laboratories. The other is a 17-gene screening test for hereditary colorectal cancers. Both were developed in collaboration with the Mayo Clinic Center for Individualized Medicine.
Explore further: Mayo Clinic shares lessons learned from genomics clinic for sequencing-based cancer care and diagnostics
Medical Xpress on facebook
Related Stories
Mayo Clinic shares lessons learned from genomics clinic for sequencing-based cancer care and diagnostics
Apr 09, 2014
It has been 1.5 years since Mayo Clinic opened the world's first integrated multidisciplinary genomics service, the Individualized Medicine Clinic, which uses genomics and next-generation sequencing technologies to personalize ...
Mayo Clinic launches whole genome breast cancer study
Apr 09, 2012
The Breast Cancer Genome Guided Therapy Study (BEAUTY Project) will help physicians tailor chemotherapy to breast cancer patients based on their individual genomes and the genomes of their tumors. Mayo Clinic researchers ...
Scientists propose a breast cancer drug for bladder cancer patients
Jan 22, 2014
Researchers at Mayo Clinic have found amplification of HER2, a known driver of some breast cancers, in a type of bladder cancer called micropapillary urothelial carcinoma (MPUC) and have shown that the presence of HER2 amplification ...
Physicians target the genes of lung, colon cancers
Apr 16, 2014
(Medical Xpress)—University of Florida physicians and researchers are collaborating to map the genes of different types of cancer, and then deliver medication to attack cancer at its source.
Researches discovered genes that predict whether trastuzumab will work for breast cancer patients
Dec 08, 2012
Adding the drug trastuzumab to chemotherapy prevents cancer recurrence and improves survival in a large number of women with early stage HER2-positive breast cancer. But trastuzumab does not stop tumors from returning in ...
Recommended for you
Imaging gives clearer picture of cancer drugs' chances of success
1 hour ago
The quest for new cancer treatments could be revolutionised by advances in technology that can visualise living cells and tissues, scientists claim.
Researchers identify mechanism of cancer caused by loss of BRCA1 and BRCA2 gene function
1 hour ago
Inherited mutations in the BRCA1 or BRCA2 tumor suppressor genes are by far the most frequent contributors to hereditary cancer risk in the human population, often causing breast or ovarian cancer in young women of child-bearing ...
Breast cancer patients place huge emphasis on gene expression profiling test
2 hours ago
Gene expression profiling tests play a critical role when women with early-stage breast cancer decide whether to have chemotherapy, but many of them do not fully understand what some of the test results mean, new research ...
Clinical trials to investigate prostate cancer treatment
4 hours ago
The way prostate cancer is treated could have a radical re-think as two international clinical trials go ahead.
Receiving chemotherapy after a breast cancer diagnosis may affect a patient's employment
12 hours ago
A new study has found that loss of paid employment after a diagnosis of early-stage breast cancer may be common and potentially related to the type of treatment patients received. Published early online in Cancer, a peer ...
Docs, patients have different attitudes toward end-of-life care
20 hours ago
(HealthDay)—Attitudes toward end-of-life resource allocation differ for patients with cancer and their caregivers and for physicians, according to a study published online April 24 in JAMA Otolaryngology-Head & ...
User comments
© Medical Xpress 2011-2014, Science X network
Mayo Clinic announces the launch of CANCP, a new gene panel cancer test to help tailor chemotherapy to the individual patient based on the unique genomic signature of the patient's tumor. CANCP, an abbreviation for Solid Tumor Targeted Cancer Gene Panel by Next-Generation Sequencing, scans specific regions in 50 genes known to affect tumor growth and response to chemotherapy. The test is now available to Mayo Clinic patients and to providers worldwide through Mayo Medical Laboratories.
"Every patient's cancer is different, and oncology is moving away from treating cancer based on its location in the body in favor of selecting the best medication for the individual patient based on molecular changes in the tumor," says Axel Grothey, M.D., a Mayo Clinic oncologist who orders CANCP on selected tumors. "This test helps providers identify such molecular changes without infusing irrelevant details from genes that we know will not affect our choice of medications."
The test is a hotspot panel, which means it scans specific regions of individual genes—rather than the entire gene—in search of tumor mutations that influence response to chemotherapy. It is designed for testing of solid tumors and focuses on clinically actionable alterations.
"We worked closely with oncologists, pathologists and molecular geneticists to develop and implement a next-generation sequencing assay that will have actionable results for providers," says Benjamin Kipp, Ph.D., a Mayo Clinic molecular geneticist and CANCP's lead designer. "This test focuses on results that oncologists can use to help find the right drug the first time."
Testing is conducted in the CLIA-certified Next-Generation Sequencing Lab of the Mayo Clinic Department of Laboratory Medicine and Pathology (DLMP). This is the second next-generation sequencing panel test offered by DLMP and Mayo Medical Laboratories. The other is a 17-gene screening test for hereditary colorectal cancers. Both were developed in collaboration with the Mayo Clinic Center for Individualized Medicine.
Explore further: Mayo Clinic shares lessons learned from genomics clinic for sequencing-based cancer care and diagnostics
Medical Xpress on facebook
Related Stories
Mayo Clinic shares lessons learned from genomics clinic for sequencing-based cancer care and diagnostics
Apr 09, 2014
It has been 1.5 years since Mayo Clinic opened the world's first integrated multidisciplinary genomics service, the Individualized Medicine Clinic, which uses genomics and next-generation sequencing technologies to personalize ...
Mayo Clinic launches whole genome breast cancer study
Apr 09, 2012
The Breast Cancer Genome Guided Therapy Study (BEAUTY Project) will help physicians tailor chemotherapy to breast cancer patients based on their individual genomes and the genomes of their tumors. Mayo Clinic researchers ...
Scientists propose a breast cancer drug for bladder cancer patients
Jan 22, 2014
Researchers at Mayo Clinic have found amplification of HER2, a known driver of some breast cancers, in a type of bladder cancer called micropapillary urothelial carcinoma (MPUC) and have shown that the presence of HER2 amplification ...
Physicians target the genes of lung, colon cancers
Apr 16, 2014
(Medical Xpress)—University of Florida physicians and researchers are collaborating to map the genes of different types of cancer, and then deliver medication to attack cancer at its source.
Researches discovered genes that predict whether trastuzumab will work for breast cancer patients
Dec 08, 2012
Adding the drug trastuzumab to chemotherapy prevents cancer recurrence and improves survival in a large number of women with early stage HER2-positive breast cancer. But trastuzumab does not stop tumors from returning in ...
Recommended for you
Imaging gives clearer picture of cancer drugs' chances of success
1 hour ago
The quest for new cancer treatments could be revolutionised by advances in technology that can visualise living cells and tissues, scientists claim.
Researchers identify mechanism of cancer caused by loss of BRCA1 and BRCA2 gene function
1 hour ago
Inherited mutations in the BRCA1 or BRCA2 tumor suppressor genes are by far the most frequent contributors to hereditary cancer risk in the human population, often causing breast or ovarian cancer in young women of child-bearing ...
Breast cancer patients place huge emphasis on gene expression profiling test
2 hours ago
Gene expression profiling tests play a critical role when women with early-stage breast cancer decide whether to have chemotherapy, but many of them do not fully understand what some of the test results mean, new research ...
Clinical trials to investigate prostate cancer treatment
4 hours ago
The way prostate cancer is treated could have a radical re-think as two international clinical trials go ahead.
Receiving chemotherapy after a breast cancer diagnosis may affect a patient's employment
12 hours ago
A new study has found that loss of paid employment after a diagnosis of early-stage breast cancer may be common and potentially related to the type of treatment patients received. Published early online in Cancer, a peer ...
Docs, patients have different attitudes toward end-of-life care
20 hours ago
(HealthDay)—Attitudes toward end-of-life resource allocation differ for patients with cancer and their caregivers and for physicians, according to a study published online April 24 in JAMA Otolaryngology-Head & ...
User comments
© Medical Xpress 2011-2014, Science X network
0 comments:
Post a Comment